Alyeska Investment Group
AGRX

Alyeska Investment Group’s Agile Therapeutics AGRX Stock Holding History

Alyeska Investment Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-130
Closed -$666K – 549
2018
Q1 		$666K Sell
130
-28
-18% -$185K 0.01% 408
2017
Q4 		$851K Sell
158
-262
-62% -$2.44M 0.01% 388
2017
Q3 		$3.75M Buy
+420
New +$3.23M 0.03% 313
2014
Q4 		– Sell
-13
Closed -$189K – 542
2014
Q3 		$189K Sell
13
-76
-85% -$1.17M ﹤0.01% 372
2014
Q2 		$1.55M Buy
+89
New +$1.29M 0.03% 330

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's AGRX Position: Q2 2018 in Review

Alyeska Investment Group sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 130 shares — an estimated $666K sold.

Alyeska Investment Group first reported a position in AGRX in Q2 2014 and held it in 5 quarters. The position peaked at $3.75M in Q3 2017. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Alyeska Investment Group reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 130 Agile Therapeutics shares in Q2 2018, an estimated $666K.
  • Alyeska Investment Group first reported a position in Agile Therapeutics in Q2 2014 and held it in 5 quarters.
  • Alyeska Investment Group's Agile Therapeutics position peaked at $3.75M in Q3 2017.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.